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Angiotensin II and L-arginine in tissue fibrosis: More than blood
pressure. Angiotensin II (Ang H) blockade and restriction of dietary
protein are thought to retard progression of renal disease primarily by
reducing glomerular capillary pressure and thereby reducing injury to
renal tissues. Relatively recent data suggest that both of these therapies
may also act through pressure-independent mechanisms to reduce repair
processes that follow tissue injury and which, if not self-limited, can
continue to cause tissue fibrosis and organ failure. We review recent data
suggesting that Ang II is a profibrotic molecule independent of blood
pressure. Therapeutic actions of dietary restriction of total protein and
restriction of the amino acid L-arginine that appear independent of
pressure are also discussed. These effects are separated into those that
reduce injury and those that reduce tissue repair. Finally, we ask whether
the Ang II blockade or restriction of dietary protein could be more
effective if they were aimed not only at limiting injury, but also at halting
excessive repair.
Progressive tissue fibrosis is characterized by excessive accumu-
lation of extracellular matrix and subsequent progressive loss of
organ function. This process appears to be independent of the
primary underlying disorder and occurs in all organ systems. It is
likely that the extent of fibrosis reflects both the duration and
severity of tissue injury and the extent of activation of the repair
process. Data from numerous studies of experimental and human
diseases suggest that persistent overexpression of the cytokine
transforming growth factor beta (TGF-j3) is a key factor in the
transition from initial tissue injury to tissue fibrosis [11. Neutral-
izing the actions of TGF-13 with either an antibody or the
proteoglycan decorin has been shown to prevent excessive matrix
accumulation after tissue injury [2, 3]. We would like to focus here
on the idea that the treatment of tissue fibrosis can aim to limit
tissue injury or to halt excessive tissue repair.
In recent years substantial evidence has accumulated which
suggests that blockade of angiotensin II (Ang II) and manipula-
tions of dietary protein intake are effective in slowing the progres-
sion of fibrotic renal diseases [4—7]. Both increased Ang II and
high dietary protein increase glomerular capillary pressure and it
has long been thought that the therapeutic effects of Ang II
blockade or low dietary protein act by decreasing glomerular
pressure and thus decreasing tissue injury. However, considerable
data has accumulated suggesting that Ang II and low dietary
protein have important blood pressure-independent effects on the
overexpression of TGF-p and on the accumulation of matrix
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proteins. In addition, there are new data suggesting that low
dietary intake of the amino acid L-arginine may be an important
aspect of the therapeutic effect of low dietary protein by limiting
both tissue injury and TGF-13-mediated tissue repair. In this
review we will summarize our current understanding of the role of
Ang II, dietary protein and L-arginine in fibrotic disease. We will
attempt to separate their effects on injury and repair. Finally, we
will ask whether Ang II blockade and/or restriction of dietary
protein could be more effective therapies if they were aimed not
only at limiting injury, but also at halting excessive repair.
Angiotensin II: Role in tissue injury
Ang II is a long known potent vasoconstrictor. Increased levels
induce systemic and local hypertension which acts as injury to
tissues. In the kidney, increased levels of Ang II lead to glomer-
ular hypertension and are an important factor in the progression
of renal disease. For example, systemic increases in Ang II
induced by clamping of one of the renal arteries, leads to systemic
hypertension and subsequent glomerular and tubulointerstitial
fibrosis in the nonclamped kidney [8]. Similar effects in both
kidneys have been shown with intravenously infused Ang II [9].
Local generation of Ang II has also been implied by numerous
studies as recedtly reviewed by Rosenberg et a! [10]. Whether Ang
II comes from the systemic circulation or is produced locally in
diseased tissues, it acts by increasing glomerular capillary pres-
sure. In numerous animal models, blockade of Ang II with
angiotensin converting enzyme inhibitors (ACEI) or Ang II
receptor antagonists reduces glomerular hypertension and re-
duces hypertensive tissue injury [10].
Angiotensin II: Role in tissue repair
Ang II blockade was initially used as a therapy for hypertension.
However, superiority of ACE-inhibition versus other hypertensive
drugs for the treatment of renal fibrotic disease was first suggested
when it was found that both antihypertensive triple therapy
(reserpine, hydralazine and hydrochlorothiazide) as well as the
ACE-inhibitor captopril effectively lowered systemic hyperten-
sion, while only captopril significantly reduced proteinuria and
histological signs of glomerulosclerosis [11]. The superior effect of
ACE-inhibition is thought to be related primarily to the fact that
it better controls glomerular hypertension and thereby reduces
glomerular injury. However, considerable evidence now exists that
Ang II has pressure-independent effects on tissue repair so that
the superiority of ACE-inhibition over conventional antihyperten-
sive therapies may result from blockade of these fibrotic pathways.
Supporting this concept are data in models of lung and liver
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fibrosis in which hypertension is not thought to be a factor.
Treatment with captopril effectively reduces matrix accumulation
and histological signs of sclerosis [12, 13].
Ang II: Pressure-independent effects on TGF-j3 synthesis and
mesangial cell matrix production
A working paradigm of our laboratory is that where there is
overexpression of TGF-13 there is matrix accumulation and fibro-
sis. Thus, it was of interest that in 1992, Wolf, Haberstroh and
Neilson added Aug II to cultured mesangial cells and observed
increased collagen synthesis [14]. Mesangial cells are the key
producers of extracellular matrix in progressive glomerulosclero-
sis. Itoh et al then demonstrated that the addition of Ang II to
vascular smooth muscle cells stimulates the secretion of TGF-13
[15]. At that point we hypothesized that Aug II enhances matrix
production and fibrosis by induction of TGF-/3. Using cultured
mesangial cells, where blood pressure is not a factor, we found a
molecular cascade involving Ang II stimulation of TGF-13 synthe-
sis and TGF-/3 stimulation of matrix protein synthesis. In partic-
ular, we found that: (1) exogenous Ang II stimulated the synthesis
of TGF-/31 mRNA and protein levels in a time- and dose-
dependent manner. This was paralleled by time- and dose-
dependent increases in mRNA and protein for matrix compo-
nents biglycan, fibronectin and type I collagen. (2) Addition of the
Ang II receptor type 1 antagonist saralasin blocked the induction
of both matrix and TGF-13 synthesis. (3) Ang II increased the
conversion of latent to active TGF-/3. (4) Addition of a neutral-
izing antibody to TGF-f3 prevented the Ang TI-induced increase in
matrix production. (5) Infusion of Ang II into normal rats for
seven days significantly increased glomerular TGF-f3 and collagen
type 1 mRNA expression [16]. Taken together, these results
suggest that Ang II, separate from its effects on blood pressure
and tissue injury, contributes to the excessive repair that charac-
terizes fibrosis by inducing TGF-/3 which then induces matrix
protein synthesis.
Ang II: Pressure-independent effects on the plasmin protease
system
In addition to its effects on matrix synthesis, recent reports have
suggested that Ang II up-regulates plasminogen activator inhibi-
tor type 1, or PAT-I, in cultured brain astrocytes, vascular
endothelial cells and vascular smooth muscle cells [17—19]. PAl-i
inhibits the plasminogen activators u-PA and t-PA, which convert
plasminogen by plasmin. Plasmin generated can degrade a num-
ber of matrix components and can also activate metalloprotein-
ases, which degrade collagens [201. Baricos et al [201 have recently
shown that plasmin is a key mediator of mesangial cell matrix
degradation. Thus, inhibition of plasmin generation by increasing
PAl-i would be expected to be profibrotic by decreasing the rate
of matrix degradation. This idea is supported by a recent study
where the fibrotic response to lung injury induced by bleomycin
was greatly diminished in PAl-i knock-out mice while genetic
overexpressors showed increased collagen deposition in response
to bleomycin [21].
in addition to its actions to up-regulate matrix protein synthesis,
TGF-/3 is an important regulator of the plasmin protease system.
In normal glomeruli, exogenously added TGF-f3 significantly
decreased the activity of plasminogen activator and increased
PAl-i synthesis [22]. In glomeruli from rats with mesangial
proliferative glomerulonephritis induced by injection of anti-
thymocyte serum (ATS), TGF-/3 overexpression correlated with
decreased PA activity, markedly increased PAl-I production and
increased PAl-I deposition into matrix. This increase in glomer-
ular PAl-I deposition was blocked when the rats were treated with
a neutralizing antibody to TGF-f3 [22].
We recently hypothesized that the effect of Ang lion the PAl-I
system is also mediated through the induction of TGF-p. Again,
using the blood pressure-independent system of cultured mesan-
gial cells, we found a dual effect of Ang II on PAl-I mRNA and
protein synthesis. The early response to Ang II was a rapid and
direct transcriptional up-regulation of the PAT-i gene and was
independent of TGF-f3. In order for this PAl-i increase to be
sustained, TGF- synthesis was required as shown by the fact that
addition of TGF-j3 neutralizing antibody largely blocked the
increase seen at 24 hours [23]. These data suggest that increased
PAT-I synthesis is yet another profibrotic action of Ang II. Taken
together, these studies suggest that Ang II may contribute to
excessive tissue repair in vivo, both by induction of TGF-f3 and
through TGF-13-independent actions. These pressure-indepen-
dent and injury-independent effects of Ang II on TGF-f3, matrix
accumulation and matrix degradation suggest another explanation
for the superior antifibrotic actions of Ang Ii blockade over
conventional antihypertensive therapies seen in renal sclerosis.
Dietary protein: Role in tissue injury
Like Ang II, high dietary protein intake is also considered to be
an important injurious substance and analogous to blockade of
Ang II, restriction of dietary protein diet is a relatively old therapy
for renal disease. In a number of experimental kidney diseases,
dietary protein restriction has been shown to be beneficial [24—
261. In human progressive renal diseases, low protein diet effec-
tively decreases proteinuria and slows the loss of GFR [6, 7, 27,
28]. Because dietary protein restriction is associated with marked
reductions in intraglomerular pressure, it has been assumed that
its antifibrotic actions are primarily mediated by reducing pres-
sure-induced injury. However, recent data suggest that low dietary
protein may also have pressure-independent therapeutic actions
on tissue repair.
Dietary protein: Role in tissue repair
ATS-induced mesangial proliferative glomerulonephritis is a
well-defined model of renal tissue injury and subsequent repair, in
which high glomerular pressure is not thought to be a factor [29,
30]. Injection of ATS leads to complement-dependent selective
mesangial cell lysis. The repair process that follows is character-
ized by mesangial cell proliferation, overexpression of TGF-J3 and
excessive extracellular matrix accumulation. If equal ATS-induced
injury is achieved and then animals are placed on either normal or
low protein diets, those fed low protein had significant reductions
in proteinuria, TGF-13 overexpression and accumulation of matrix
proteins compared to those fed normal protein diets [31]. This
study suggests that the low protein diet has a direct, blood-
pressure-independent effect on TGF-f3-driven tissue repair. Sim-
ilar effects of low protein diet on TGF-13 overexpression and
glomerulosclerosis have recently been shown in rat models of
puromycin aminonucleoside and adriamycin induced glomerular
nephrosis [32, 33].
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We asked what might be responsible for this effect of dietary
protein and were struck that the amino acid L-arginine appears to
be a substrate in a number of pathways involved in tissue injury
and repair (Fig. 1). L-arginine is metabolized by the constitutive
form of nitric oxide synthase, eNOS, to form NO in small
quantities at endothelial sites where it serves as a potent vasodi-
lator [34]. L-arginine is also substrate for NO produced by the
cytokine inducible NOS, iNOS, which has been implicated in
tissue injury [35—37]. On the tissue repair side, L-arginine,
through the enzyme arginase, is substrate for polyamines which
are required for cell proliferation, a process central to tissue
repair [38]. L-arginine is also a substrate for L-proline, which is a
major constituent of the collagen that makes up fibrotic extracel-
lular matrix. L-proline accounts for 11 to 13% of the amino acid
residues in mammalian collagens, while its hydroxylated form
(4-hydroxy-L-proline) accounts for a further 8 to 10% [39], so that
up to 23% of the amino acids in collagen come from L-proline.
Dietary L-arginine intake is classified as semi-essential [40].
The major site of endogenous L-arginine synthesis is the proximal
tubule of the kidney [41—431. Under normal physiological condi-
tions dietary L-arginine intake is dispensable and whole body
arginine homeostasis can be achieved by endogenous L-arginine
synthesis. However, the rate of endogenous L-arginine synthesis is
constant and in times of high L-arginine demand such as in growth
or injury, dietary L-arginine becomes essential [44]. Studies in
dermal wound healing have shown that arginine metabolism is
highly activated following injury and local L-arginine is rapidly
depleted [45]. Local depletion of L-arginine suggested that avail-
ability of the substrate L-arginine may become rate limiting to the
L-arginine pathways during injury and repair. We asked whether
low dietary L-arginine might be an important therapeutic compo-
nent of low-protein diet and hypothesized that its action would be
to decrease available L-arginine for NO generation during tissue
injury, thus possibly limiting injury. Decreased availability of
arginine for polyamine and collagen synthesis during tissue repair
might limit cell proliferation and pathological matrix synthesis.
Dietary L-arginine: Role in tissue repair
As mentioned above, L-arginine is a precursor for the genera-
tion of polyamines and L-proline [38]. The first enzyme in the
generation of polyamines and L-proline from L-arginine is argi-
nase, which forms urea and the non-protein amino acid L-
ornithine. L-ornithine is then further metabolized to putrescine by
ornithine decarboxylase (ODC), the major regulatory enzyme in
polyamine synthesis. The generation of L-proline from L-orni-
thine requires only two enzymes, ornithine-amino-transferase
(OAT) and pyrroline-5-carboxylate reductase. In ATS-induced
glomerulonephritis, we have recently demonstrated that L-argi-
nine pathways are profoundly activated [501. The initial mesangial
cell lysis phase is characterized by high 1NOS expression and
markedly elevated NO synthesis. Arginase activity, required for
metabolism of L-arginine to polyamines and L-proline, was
increased for the first five days. The polyamine generating enzyme
ODC was up-regulated for three days after disease induction and
coincided with the onset of glomerular mesangial cell prolifera-
tion. Expression of the gene for OAT, the first enzyme in local
L-proline synthesis from L-ornithine, was increased from day 1
and paralleled the course of glomerular matrix synthesis. This
up-regulation of the polyamine and L-proline pathways during the
repair phase is consistent with the idea that these pathways may
have important roles in proliferation and matrix accumulation,
respectively.
To further evaluate the role of dietary L-arginine in the
beneficial effects of low protein diets in fibrotic renal diseases, we
tested the effect of isocaloric diets differing in their L-arginine
and/or total protein content after the ATS glomerulonephritis was
induced and the same degree of tissue injury had been achieved
[52]. Seven days after disease induction, the kidneys of rats fed a
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Fig. 1. Metabolic pathways using L-arginine as substrate.
The role of L-arginine in tissue injury derives from the fact that
Arginase it is the sole substrate for the cytokine-inducible nitric oxide
synthase (iNOS). This enzyme produces large quantities of NO,
L-Ornithine which have been shown to cause tissue injury in models of
autoimmune disease, including those of alveolitis, arthritis and
glomerulonephritis [35—37]. In several models of renal disease,
ODC OAT including ATS-induced glomerulonephritis, induction of disease isfollowed by a marked increase in glomerular iNOS expression and
NO synthesis [46—50]. We therefore asked whether the ATS-
induced mesangial cell lysis is mediated by NO and whether
Polyamines L-Proline limitation of dietary L-arginine intake may be protective. In rats
pre-treated with the NO synthase inhibitor L-nitro-monomethyl-
L-arginine (L-NMMA) thirty minutes before ATS administration,
we found that mesangial cell lysis was inhibited by 90%. There was
no difference in the number of infiltrating macrophages and
monocytes compared to disease control rats. In addition, if dietary
L-arginine intake was reduced through low protein feeding for
one week, ATS-induced mesangial cell lysis was significantly
lowered. Furthermore, normalization of the L-arginine intake by
supplementation of low protein diet with L-arginine in the
drinking water resulted in increased mesangial cell lysis [51].
These findings demonstrate that the injury in ATS-glomerulone-
phritis is NO dependent and that dietary L-arginine restriction
limits tissue injury by limiting the amount of NO produced, a
mechanism that may have great importance in the beneficial
effects of low protein diets in renal diseases.
Dietary protein: Role of L-arginine content
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AT! %
Citation Disease model ACE! blocker TGF-
and an average value was used in Table 1. Consistent with
previously published data, renal fibrosis was not stopped in the
studies summarized here. However, in most of these studies
X 60 TGF-/3 expression was not reduced to normal (Table 1).
X 50 Work with chronic models of fibrosis suggests that after a point
x x 50 further tissue injury may not be required to sustain TGF-f3
X 100 overexpression [1, 631. For example, in ATS-induced glomerulo-
X X 100 nephritis, a second shot leads to progressive glomerulosclerosis
X and sustained overexpression of TGF-J3 without further injury
X 90 [63]. Thus, it appears possible that Ang II blockade and dietary
protein restriction may be only moderately effective because they
X X 75 aim to reduce injury when in fact there are components of the
X Z. excessive repair process that after a point are self-perpetuated.
Thus, Ang II blockade or low protein diet might well be more
effective therapies if treatment regimens were aimed at lowering
both glomerular pressure and TGF-p overexpression. We believe
that efforts aimed at answering this question are worthwhile.normal protein diet showed marked intraglomerular matrix accu-
mulation and overexpression of TGF-131 mRNA and protein.
Consistent with our earlier studies [31], a low protein diet
effectively prevented these fibrotic changes. Interestingly, a simi-
lar therapeutic effect could be achieved in rats fed an amino acid
diet equaling those present in normal protein but with reduced
L-arginine content. In contrast, when the low protein diet was
supplemented with L-arginine in the drinking water, the glomer-
ular matrix accumulation and TGF-13 expression were comparable
to those of rats on a normal protein diet. These results suggest
that in the repair phase of ATS-induced glomerulonephritis,
L-arginine is involved in mesangial cell proliferation, glomerular
matrix deposition and TGF-/3 overexpression. This L-arginine
effect on repair may be due to a limitation of substrate for
polyamine and L-proline production. Analogous to dermal
wounding, dietary L-arginine restriction may intensify local L-
arginine depletion such that substrate availability becomes the
rate-limiting step for the synthesis of polyamines and L-proline.
Could angiotensin blockade and/or restriction of dietary
protein be more effective therapies if they were aimed both to
limit injury and halt excessive repair?
In this review we have attempted to show that two frequently
used therapies, angiotensin blockade and low protein diet, may
have effects both on tissue injury and on the excessive repair that
characterizes tissue fibrosis. Conventionally these therapies have
aimed at reducing glomerular capillary pressure and the injury
that results. We know from considerable animal and human
experience that neither these drugs nor a low protein diet stop
disease, they only retard progression. If Ang II and high dietary
protein do indeed have pressure-independent effects on excessive
repair in vivo, an interesting question is whether these traditional
therapies could not be more effective if they were optimized for
these actions.
TGF-/3 overexpression is a key event in tissue fibrosis, and an
ever-growing body of data support the idea that normalization of
TGF-f3 expression is a reasonable therapeutic target. Very recent
studies in a number of animal models of renal disease have
measured the effect of either ACE inhibition or Ang II receptor
blockade on the overexpression of TGF-13. A summary of these
studies is presented in Table 1. In a number of these studies the
design included both experimental groups treated with ACE
inhibition and groups treated with receptor blockade. Where both
drugs were used, the effects on TGF-/3 expression were similar
Table 1. Angiotensin II blockade decreases TGF-f3 expression
Junaid et al [53]
Kim et al [541
Ohta et al [55]
Shankland et al [56]
Kim et al [57]
Nishimura et al [58]
Pimentel et al [591
Ruiz-Ortega et al [60]
Shihab et al [61]
Ishidoya et al [62]
Remnant kidney
DOCA-salt hypertension
SHR
Uni-Nx SHR
SHR-SP
Human IgA
Ureteral obstruction
Immune complex
nephritis
CsA nephropathy
Ureteral obstruction
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